Form 10-Q Ultragenyx Pharmaceutica For: Sep 30
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Ultragenyx Pharma (RARE) PT Raised to $116 at Cowen
October 28, 2020 6:59 AM EDTCowen analyst Yaron Werber raised the price target on Ultragenyx Pharma (NASDAQ: RARE) to $116.00 (from $90.00) while maintaining an Outperform rating.
The analyst commented, "RARE reported Q3:20 earnings with OpEx of $132M v our $128M estimates & steady growth in sales of Crysvita & Dojolvi.... More
